Yahoo
NSE - Delayed Quote INR

Alembic Pharmaceuticals Limited (APLLTD.NS)

797.85 +3.00 (+0.38%)
At close: October 30 at 3:30:03 PM GMT+5:30
Chart Range Bar
Loading chart for APLLTD.NS
  • Previous Close 794.85
  • Open 794.85
  • Bid --
  • Ask --
  • Day's Range 784.05 - 800.00
  • 52 Week Range 635.80 - 998.00
  • Volume 72,865
  • Avg. Volume 161,516
  • Market Cap (intraday) 156.828B
  • Beta (5Y Monthly) 0.32
  • PE Ratio (TTM) 22.62
  • EPS (TTM) 35.27
  • Earnings Date (est.) --
  • Forward Dividend & Yield 12.00 (1.50%)
  • Ex-Dividend Date Jul 29, 2026
  • 1y Target Est 961.80

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

alembicpharmaceuticals.com

17,244

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

APLLTD.NS
4.31%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

APLLTD.NS
10.03%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

APLLTD.NS
12.70%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

APLLTD.NS
9.37%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 21.5B
Earnings 1.73B
Profit Margin 8.05%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
5B
10B
15B
20B
8.0%
9.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

835.00
961.80 Average
797.85 Current
1,132.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.91%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    77.84B

  • Net Income Avi to Common (ttm)

    6.93B

  • Diluted EPS (ttm)

    35.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.96B

  • Total Debt/Equity (mrq)

    25.22%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: